Trainee Omnichannel Marketing (f/m/d)

Have you completed your master's degree and are now eager to take your next steps within a company? Then you've come to the right place! In our 24-month Omnichannel Marketing trainee program, you'll quickly acquire in-depth knowledge of the marketing areas of our pharmaceutical company. We want to develop with you, both professionally and personally! During the 24 months of the trainee program, you'll work through three different stations and develop and expand your skills at one of Germany's leading pharmaceutical marketing companies. The following areas can be part of your traineeship: Product Management Traditional Media: We show you how our products are created and marketed (advertisements in trade and general interest print and TV media, central coordination of marketing processes, creation of content for pharmacy sales, media planning, graphics and PR, etc.). Performance Marketing Native/Social: You will learn how ad conception and control works in the online context of native (e.g. Outbrain) and social (e.g. Facebook) and take responsibility for campaign management. SEA: You'll learn about SEA strategies and manage SEA campaigns in detail. You'll be responsible not only for finding suitable keywords and texts, but also for conducting quantitative analyses and campaign evaluations. Influencer Marketing: We'll show you how to conceptualize and coordinate influencer campaigns, including identifying suitable influencers.

We are SYNformulas – the company behind the Kijimea brand. Since our founding in 2011, we have pursued a clear vision: We want to specifically harness the potential of the microbiota (bacteria) in our intestines for a longer, healthier life – for everyone. We achieved a first major milestone on this path in 2013 with the discovery and clinical research of the unique bacterial strain B. bifidum MIMBb75 ( Kijimea Irritable Bowel Syndrome ). Since then, we have been able to noticeably improve the lives of millions of irritable bowel syndrome patients worldwide. Today, B. bifidum MIMBb75 is one of the best-researched bacterial strains in the world. Its efficacy and unique mechanism of action have been proven and published in numerous clinical studies – including in renowned journals such as The Lancet . We work with leading research institutions such as the Charité Berlin to research the connections between the microbiota (bacteria in our intestines) and allergies, skin diseases, and mental disorders. In short: We investigate how the bacteria in our gut influence a longer and healthier life. Today, we are one of the fastest-growing healthcare companies in the world. We reach our customers through a variety of channels: direct communication with doctors and pharmacists, as well as print, TV, and digital marketing. Our goal is clearly defined: By 2028, we want to make Kijimea the world's largest DTC probiotic brand, thereby giving over 50 million people a better life every year.